

Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	10/589,052; Conf. No. 5470
				<b>Filing Date</b>	September 8, 2008
				<b>First Named Inventor</b>	Kambiz Shekdar
				<b>Art Unit</b>	1654
				<b>Examiner Name</b>	Amber D. Steele
(use as many sheets as necessary)				<b>Attorney Docket Number</b>	002298-0003-101
Sheet	1	of	2		

U.S. PATENT DOCUMENTS						
Examiner initials*	Cite No. <sup>1</sup>	Document Number Number – Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/ADS/		2003/096322	05-22-2003	Giuliano et al.		
FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>1</sup> – Number <sup>2</sup> - Kind Code <sup>3</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
/ADS/		WO 200131059	05-03-2001	Molecular Light Tech Res Ltd.		
NON PATENT LITERATURE DOCUMENTS						
Examiner initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T <sup>6</sup>
/ADS/		BRAASCH et al., "Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design", Nucleic Acids Research, 30(23): 5160-5167 (2002)				
/ADS/		GAIT, "Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues", CMLS, Cell. Mol. Life Sci. 60:844-853 (2003)				
/ADS/		GOPALAKRISHNAN et al., "siRNA and DNA Transfer to Cultured Cells", Methods in Molecular Biology, 480: 31-52 (2009)				
/ADS/		HOFFMANN et al., "Expression screening of factors binding to the osteocalcin bone-specific promoter element OC Box I: isolation of a novel osteoblast differentiation-specific factor," J. Cell. Biochem. 80:156-168 (2000)				
/ADS/		KURRECK, "Antisense technologies: Improvement through novel chemical modifications", Eur. J. Biochem. 270:1628-1644 (2003)				
/ADS/		MITCHELL, "Turning the spotlight on cellular imaging", Nature Biotechnology, 19(11): 1013-1017 (2001)				
/ADS/		NESTEROVA et al., "Killing the Messenger: Antisense DNA and siRNA", Current Drug Targets, 5: 683-689 (2004)				
/ADS/		PESTOV et al., "Genetic selection of growth-inhibitory sequences in mammalian cells," Proc. Natl. Acad. Sci. USA 91:12549-12553 (1994)				

Examiner Signature	/Amber D. Steele/	Date Considered	10/27/2011
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if known</b>	
				<b>Application Number</b>	10/589,052; Conf. No. 5470
				<b>Filing Date</b>	September 8, 2008
				<b>First Named Inventor</b>	Kambiz Shekdar
				<b>Art Unit</b>	1654
				<b>Examiner Name</b>	Amber D. Steele
<b>Sheet</b>	2	<b>of</b>	2	<b>Attorney Docket Number</b>	002298-0003-101 (CHROMO/003)

U.S. PATENT DOCUMENTS			
/ADS/		ROSE, "Optimization of Transfection", Current Protocols in Neuroscience (1997) A.1B.1-A.1B.3	
/ADS/		STARK et al., "Forward genetics in mammalian cells: function approaches to gene discovery," Human Molecular Genetics 8(10):1925-1938 (1999)	
/ADS/		ZAMBROWICZ et al., "Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells," Nature 392:608-611 (1998)	
/ADS/		ZIENG et al., "A system for rapid generation of coat color-tagged knockouts and defined chromosomal rearrangements in mice," Nucl. Acids Res. 27(11):2354-2360 (1999)	

<b>Examiner Signature</b>	/Amber D. Steele/	<b>Date Considered</b>	10/27/2011
-------------------------------	-------------------	----------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**